Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Has Average Price Target of $48.43

Teva Pharmaceutical Industries logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is broadly positive: Sixteen firms have a “Moderate Buy” consensus on Teva, with an average one-year price target of $48.43; 14 rate it a buy, one a hold and one a sell.
  • Teva beat quarterly earnings expectations: It reported $0.86 per share versus the $0.72 consensus and revenue of $4.39 billion versus estimates of $4.23 billion, though revenue fell 1.9% year over year.
  • Insiders have been selling shares: Company insiders sold 715,945 shares worth about $29.1 million over the past three months. Separately, Teva announced its R&D chief medical officer is leaving, while saying its R&D priorities remain unchanged.
  • MarketBeat previews top five stocks to own in December.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the sixteen research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $48.43.

A number of research firms have commented on TEVA. Zacks Research lowered Teva Pharmaceutical Industries from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 20th. HC Wainwright reaffirmed a "buy" rating and set a $54.00 price target on shares of Teva Pharmaceutical Industries in a research report on Tuesday. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an "overweight" rating in a research report on Thursday, November 12th. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Monday, October 12th. Finally, Oppenheimer increased their price objective on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an "outperform" rating in a research report on Friday, October 9th.

Read Our Latest Research Report on TEVA

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 46,000 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the completion of the transaction, the insider owned 80,760 shares in the company, valued at $3,386,266.80. This trade represents a 36.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Richard Daniell sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $42.91, for a total value of $1,072,750.00. Following the completion of the transaction, the executive vice president owned 55,755 shares in the company, valued at approximately $2,392,447.05. This trade represents a 30.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 715,945 shares of company stock worth $29,061,351 over the last three months. 0.54% of the stock is owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently modified their holdings of the business. Integrated Wealth Concepts LLC lifted its stake in shares of Teva Pharmaceutical Industries by 68.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,780 shares of the company's stock valued at $783,000 after purchasing an additional 8,063 shares during the period. Allworth Financial LP lifted its position in shares of Teva Pharmaceutical Industries by 150.9% during the 3rd quarter. Allworth Financial LP now owns 3,202 shares of the company's stock valued at $127,000 after buying an additional 1,926 shares in the last quarter. Quantessence Capital LLC acquired a new position in Teva Pharmaceutical Industries in the third quarter valued at about $734,000. Quantitative Investment Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $228,000. Finally, Aspen Grove Capital LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $231,000. 54.05% of the stock is currently owned by institutional investors.

Key Stories Impacting Teva Pharmaceutical Industries

Here are a few of the latest stories about TEVA:

  • Positive Sentiment: Argus raised its price target to $50 from $42 and reaffirmed a Buy rating, signaling confidence in Teva’s outlook. Argus raises Teva price target
  • Neutral Sentiment: Teva reached a settlement in states’ generic-drug price-fixing litigation. The available report does not specify the settlement terms or financial impact, so the effect on the company’s liabilities is unclear. Settlement report
  • Negative Sentiment: R&D chief medical officer Eric Hughes is leaving for another opportunity. David Gardiner will lead the transition while Teva searches for a successor, potentially raising concerns about continuity in a strategically important area. The company says its R&D priorities are unchanged and reiterated its goal of $6–7 billion in innovative-medicines revenue by 2030. Teva R&D leadership transition

Teva Pharmaceutical Industries Stock Down 1.0%

Shares of NYSE TEVA opened at $42.19 on Thursday. Teva Pharmaceutical Industries has a 12-month low of $24.01 and a 12-month high of $44.57. The firm has a market cap of $49.16 billion, a PE ratio of 98.11, a P/E/G ratio of 3.69 and a beta of 0.97. The company's fifty day simple moving average is $40.51 and its 200 day simple moving average is $35.21. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.14. The firm had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business's quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company earned $0.78 EPS. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

See Also

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?

Before you consider Teva Pharmaceutical Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.

While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines